证券之星消息，惠泰医疗近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润盈利 8.206亿元，同比增长21.91%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。 惠泰医疗（688617）主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高 新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医疗器械为重点发 展方向的业务布局。 ...

近5日资金流向一览见下表： 证券之星消息，截至2026年2月9日收盘，惠泰医疗(688617)报收于229.38元，下跌0.27%，换手率 0.52%，成交量7315.0手，成交额1.67亿元。 2月9日的资金流向数据方面，主力资金净流入1289.18万元，占总成交额7.71%，游资资金净流出 1122.48万元，占总成交额6.71%，散户资金净流出166.7万元，占总成交额1.0%。 惠泰医疗2025年三季报显示，前三季度公司主营收入18.67亿元，同比上升22.47%；归母净利润6.23亿 元，同比上升18.02%；扣非净利润6.02亿元，同比上升18.5%；其中2025年第三季度，公司单季度主营 收入6.54亿元，同比上升24.77%；单季度归母净利润1.98亿元，同比上升6.77%；单季度扣非净利润1.91 亿元，同比上升6.1%；负债率12.24%，投资收益1390.22万元，财务费用-811.65万元，毛利率73.19%。 惠泰医疗（688617）主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高 新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医 ...

Core Viewpoint - Huatai Medical (688617) experienced a decline of 2.15% in stock price, closing at 279.0 yuan on November 13, 2025, with a trading volume of 6,989 hands and a turnover of 196 million yuan [1]. Fund Flow Summary - On November 13, 2025, the net outflow of main funds was 1.27 million yuan, accounting for 0.65% of the total turnover, while retail funds saw a net inflow of 2.80 million yuan, representing 1.43% of the total turnover [1][2]. - Over the past five days, the stock has shown fluctuating fund flows, with significant net outflows from main funds on several days, particularly on November 10, where the outflow reached 15.36 million yuan [2]. Financing and Margin Trading Data - On November 13, 2025, the financing balance was 151 million yuan, with a net financing purchase of 5.35 million yuan. The margin trading balance stood at 168 million yuan [3]. - The stock's margin trading data indicates a consistent level of activity, with a total of 6,100 shares remaining in the margin account as of November 13, 2025 [3]. Company Performance Metrics - Huatai Medical's market capitalization is 39.34 billion yuan, ranking 4th in the medical device industry, while its net profit of 623 million yuan places it 9th in the same sector [4]. - The company reported a year-on-year revenue increase of 22.47% for the first three quarters of 2025, with a net profit growth of 18.02% [4]. - The gross profit margin stands at 73.19%, significantly higher than the industry average of 51.22%, indicating strong operational efficiency [4]. Institutional Ratings - In the last 90 days, 14 institutions have rated Huatai Medical, with 12 buy ratings and 2 hold ratings, suggesting a positive outlook among analysts [5]. - The average target price set by institutions over the past 90 days is 363.54 yuan, indicating potential upside from the current trading price [5].

证券之星消息，截至2025年9月3日收盘，惠泰医疗(688617)报收于315.42元，上涨3.12%，换手率1.69%，成交量2.38万手，成交额7.5亿元。 9月3日的资金流向数据方面，主力资金净流入1.07亿元，占总成交额14.34%，游资资金净流出1.04亿元，占总成交额13.89%，散户资金净流出 333.64万元，占总成交额0.45%。 近5日资金流向一览见下表： | 日期 | | 涨跌幅 融资余额(元) | 融资净买入(元) | 融券余量(股) | 融券净卖出(股) | 融资融券余额(元) | | --- | --- | --- | --- | --- | --- | --- | | 2025-09-03 | 3.12% | 8427.71万 | 238.14万 | 3.60万 | 3366.0 | 9563.34万 | | 2025-09-02 | 0.12% | 8189.56万 | -1224.49万 | 3.26万 | 9717.0 | 9187.86万 | | 2025-09-01 | 7.43% | 9414.06万 | -1768.94万 | 2.29万 | -3768.0 | 1 ...